Bio-Techne’s Advanced Cell Diagnostics (ACD) sets new standard in spatial biology with protease-free RNAscope multiomics

Bio-Techne Corporation (NASDAQ: TECH) today announced that Advanced Cell Diagnostics (ACD), a Bio-Techne spatial biology brand, has set a new standard with the development of a next-generation, protease-free RNAscope spatial multiomics workflow.

New influenza vaccine strategies aim to enhance protection with T-cell responses

A recent review highlights the need for innovative influenza vaccines that combine T-cell and antibody responses to enhance protection across multiple strains and seasons.

May 6, 2024

New risk score identifies heart disease risk in kidney transplant patients

Using an innovative risk score assessment score, heart researchers at Intermountain Health in Salt Lake City say they can accurately predict whether patients being assessed

November 18, 2024

Physicians say transgender sports bans are a health issue

Almost half of U.S. states have banned or restricted trans youths’ access to gender-affirming puberty blockers, hormones, and surgery — and many of the same

September 19, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.